Clinical Manifestations.

Background: The impact of knowledge of β-amyloid status on cognitively unimpaired persons' cognitive test performance is unknown.

Method: Cognitively unimpaired adults aged 65-80 with a first-degree relative with AD received a dementia risk estimate and were randomly assigned to disclosure (D+) or non-disclosure (D-) of their β-amyloid PET scan result. At 6 weeks and 6 months post-disclosure, participants completed the ADCS-PACC, a composite of Free and Cued Selective Reminding (free portion), Logical Memory IIa test, Digit-Symbol Substitution, and MMSE.

Inert splint-driven oligonucleotide assembly.

In this study, we introduce a new method for oligonucleotide fragment assembly. Unlike polymerase chain assembly and ligase chain assembly that rely on short, highly purified oligonucleotides, our method, named , uses a one-tube, splint-driven assembly reaction. Splynthesis connects standard-desalted "contig" oligos (∼150 nt in length) via shorter "splint" oligos harboring 5' and 3' blocking modifications to prevent off-target ligation and amplification events.

Family Genetic Risk Communication and Reverse Cascade Testing in the BabySeq Project.

Purpose: Genomic sequencing of newborns (NBSeq) can initiate disease surveillance and therapy for children, and may identify at-risk relatives through reverse cascade testing. We explored genetic risk communication and reverse cascade testing among families of newborns who underwent exome sequencing and had a risk for autosomal dominant disease identified.

Methods: We conducted semi-structured interviews with parents of newborns enrolled in the BabySeq Project who had a pathogenic or likely-pathogenic (P/LP) variant associated with an autosomal dominant (AD) childhood- and/or adult-onset disease returned.

Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.

The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to optimize and validate biomarkers for clinical trials while sharing all data and biofluid samples with the global scientific community. ADNI has been instrumental in standardizing and validating amyloid beta (Aβ) and tau positron emission tomography (PET) imaging. ADNI data were used for the US Food and Drug Administration (FDA) approval of the Fujirebio and Roche Elecsys cerebrospinal fluid diagnostic tests.

Frailty over the rainbow: a cross-sectional study of LGBT+ adults aged over 50 years.

Objective: To investigate differences in the prevalence of frailty between LGBT+ and non-LGBT+ older adults.

Methods: A cross-sectional study involving Brazilians aged 50 and over was performed. The participants were invited to participate in an anonymous online survey between August 2019 and January 2020.